Current and emerging biomarkers for melanoma care

Biomarkers are revolutionising our understanding of melanoma by providing valuable information about a patient's unique tumour characteristics which can help guide clinical decision making. In this podcast, A/Prof Alex Menzies leads a multidisciplinary discussion on the current state of biomarker application and future prospects of biomarkers in melanoma care. They discuss emerging liquid biomarkers, such as ctDNA, MIA’s personalised immunotherapy platform that is trying to predict the likelihood of response and select patients for treatment, and the role of the gut microbiome as a potential biomarker in response and toxicity. This podcast from Melanoma Institute Australia is suitable for Medical Oncologists, Surgical Oncologists, Researchers, GPs and other healthcare professionals. LINKS: 2024 Australasian Melanoma Conference Melanoma Risk Prediction Tools Melanoma Education Portal SPEAKERS A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Ines Silva - Medical Oncologist, Melanoma Institute Australia and Blacktown Hospital | Research Scientist, Melanoma Institute Australia and The University of Sydney Prof Helen Rizos - Cancer Cell Biologist and Research Lead in the Faculty of Medicine, Health and Human Sciences at Macquarie University | Faculty Member, Melanoma Institute Australia A/Prof James Wilmott - Senior Scientist, Charles Perkins Centre, The University of Sydney| Faculty Member, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (April 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.